ArticleEuropean journal of nuclear medicine and molecular imaging2017
The value of [
Article in European journal of nuclear medicine and molecular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Qualitative and quantitative differentiation efficiency of dual-tracer PET/CT with 18F-fluorodeoxyglucose andAbdominal radiology (New York) · 2025Pooled it
- [European journal of nuclear medicine and molecular imaging · 2025Trial
- Monitoring Response to Transarterial Chemoembolization in Hepatocellular Carcinoma UsingJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020Trial
- Assessment of viable tumours by [European journal of nuclear medicine and molecular imaging · 2025Article
- 18F-5-fluoro-aminosuberic acid PET/CT imaging of oxidative-stress features during the formation of DEN-induced rat hepatocellular carcinoma.Theranostics · 2025Article
- Dual-tracer PET/CT in the management of hepatocellular carcinoma.JHEP reports : innovation in hepatology · 2024Article
- Preclinical evaluation ofEuropean journal of nuclear medicine and molecular imaging · 2023Article
- Evaluating treatment response following locoregional therapy for hepatocellular carcinoma: A review of the available serological and radiological tools for assessment.JGH open : an open access journal of gastroenterology and hepatology · 2023Review
- Review
- A Potential Prognostic Marker for Recognizing VEGF-Positive Hepatocellular Carcinoma Based on Magnetic Resonance Radiomics Signature.Frontiers in oncology · 2022Article
- Dual-tracer positron emission tomography/computed tomography as an imaging probe ofFrontiers in medicine · 2022Article
- Biological Evaluation of [Frontiers in chemistry · 2021Article
- Therapeutics for advanced hepatocellular carcinoma: Recent advances, current dilemma, and future directions.Journal of cellular physiology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis prospective study was to investigate the value of [
methodsTwenty-two patients (three women, 19 men; 62 ± 8 years) with HCC verified by histopathology were treated with TACE and bevacizumab (n = 11) or placebo (n = 11). [
resultsThe patient-related sensitivity of [
conclusionsOur study suggests that combining [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.